Cargando…

A prospective study of neurofibromatosis type 1 cancer incidence in the UK

Neurofibromatosis type 1 (NF1) is an autosomal dominant condition affecting around one in 3000 live births. The manifestations of this condition are extremely variable, even within families, and genetic counselling is consequently difficult with regard to prognosis. Individuals with NF1 are acknowle...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, L, Thompson, D, Easton, D, Ponder, B, Ponder, M, Frayling, I, Baralle, D
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2006
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360616/
https://www.ncbi.nlm.nih.gov/pubmed/16786042
http://dx.doi.org/10.1038/sj.bjc.6603227
_version_ 1782153093641666560
author Walker, L
Thompson, D
Easton, D
Ponder, B
Ponder, M
Frayling, I
Baralle, D
author_facet Walker, L
Thompson, D
Easton, D
Ponder, B
Ponder, M
Frayling, I
Baralle, D
author_sort Walker, L
collection PubMed
description Neurofibromatosis type 1 (NF1) is an autosomal dominant condition affecting around one in 3000 live births. The manifestations of this condition are extremely variable, even within families, and genetic counselling is consequently difficult with regard to prognosis. Individuals with NF1 are acknowledged to be at increased risk of malignancy. Several studies have previously attempted to quantify this risk, but have involved relatively small study populations. We present prospective data from 448 individuals with NF1 with a total of 5705 years of patient follow-up. These data have been collected via the UK NF1 association for patients. Demographic information on the affected individuals was cross-referenced with UK cancer registry data by the UK Office of National Statistics. The overall risk of cancer was 2.7 times higher in this cohort of NF1 patients than in the general population (95% confidence interval (CI) 1.9–3.7). The cumulative risk of a malignancy by age 50 years was 20% (95% CI 14–29%); beyond this age, the risk of cancer was not significantly elevated (P=0.27). The most frequent types of cancer were connective tissue (14% risk by age 70, 95% CI 7.8–24%) and brain tumours (7.9, 95% CI 3.9–16%). There was no statistically significant excess of cancers at other sites (P=0.22).
format Text
id pubmed-2360616
institution National Center for Biotechnology Information
language English
publishDate 2006
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23606162009-09-10 A prospective study of neurofibromatosis type 1 cancer incidence in the UK Walker, L Thompson, D Easton, D Ponder, B Ponder, M Frayling, I Baralle, D Br J Cancer Genetics and Genomics Neurofibromatosis type 1 (NF1) is an autosomal dominant condition affecting around one in 3000 live births. The manifestations of this condition are extremely variable, even within families, and genetic counselling is consequently difficult with regard to prognosis. Individuals with NF1 are acknowledged to be at increased risk of malignancy. Several studies have previously attempted to quantify this risk, but have involved relatively small study populations. We present prospective data from 448 individuals with NF1 with a total of 5705 years of patient follow-up. These data have been collected via the UK NF1 association for patients. Demographic information on the affected individuals was cross-referenced with UK cancer registry data by the UK Office of National Statistics. The overall risk of cancer was 2.7 times higher in this cohort of NF1 patients than in the general population (95% confidence interval (CI) 1.9–3.7). The cumulative risk of a malignancy by age 50 years was 20% (95% CI 14–29%); beyond this age, the risk of cancer was not significantly elevated (P=0.27). The most frequent types of cancer were connective tissue (14% risk by age 70, 95% CI 7.8–24%) and brain tumours (7.9, 95% CI 3.9–16%). There was no statistically significant excess of cancers at other sites (P=0.22). Nature Publishing Group 2006-07-17 2006-06-20 /pmc/articles/PMC2360616/ /pubmed/16786042 http://dx.doi.org/10.1038/sj.bjc.6603227 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Genetics and Genomics
Walker, L
Thompson, D
Easton, D
Ponder, B
Ponder, M
Frayling, I
Baralle, D
A prospective study of neurofibromatosis type 1 cancer incidence in the UK
title A prospective study of neurofibromatosis type 1 cancer incidence in the UK
title_full A prospective study of neurofibromatosis type 1 cancer incidence in the UK
title_fullStr A prospective study of neurofibromatosis type 1 cancer incidence in the UK
title_full_unstemmed A prospective study of neurofibromatosis type 1 cancer incidence in the UK
title_short A prospective study of neurofibromatosis type 1 cancer incidence in the UK
title_sort prospective study of neurofibromatosis type 1 cancer incidence in the uk
topic Genetics and Genomics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360616/
https://www.ncbi.nlm.nih.gov/pubmed/16786042
http://dx.doi.org/10.1038/sj.bjc.6603227
work_keys_str_mv AT walkerl aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT thompsond aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT eastond aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT ponderb aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT ponderm aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT fraylingi aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT baralled aprospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT walkerl prospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT thompsond prospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT eastond prospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT ponderb prospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT ponderm prospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT fraylingi prospectivestudyofneurofibromatosistype1cancerincidenceintheuk
AT baralled prospectivestudyofneurofibromatosistype1cancerincidenceintheuk